Quest Diagnostics Incorporated (DGX) files 8-K

Quest Diagnostics Incorporated (NYSE:DGX) Logo

Quest Diagnostics Incorporated (DGX) revealed 8-K form on May 17.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On May 13, 2019, the Board of Directors of Quest Diagnostics Incorporated (the ‘Company’) amended the Company’s Amended and Restated By-laws (the ‘By-Laws’) to clarify the Board’s intent that the Chief Executive Officer can remove any officer at any time. The foregoing summary is qualified in its entirety by the By-Laws filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

(a)           The following is a summary of the voting results for each matter presented to the stockholders at the 2019 Annual Meeting of Stockholders which was held on May 14, 2019.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

The stock increased 0.87% or $0.84 during the last trading session, reaching $97.23. About 899,852 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has declined 14.63% since May 17, 2018 and is downtrending. It has underperformed by 19.00% the S&P500.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $13.07 billion. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene and esoteric testing, anatomic pathology, and other diagnostic information services. It has a 18.62 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.

Investors sentiment decreased to 0.98 in 2018 Q4. Its down 0.08, from 1.06 in 2018Q3. It dived, as 66 investors sold Quest Diagnostics Incorporated shares while 168 reduced holdings. 56 funds opened positions while 173 raised stakes. 116.03 million shares or 5.89% more from 109.58 million shares in 2018Q3 were reported.
Da Davidson And reported 0.01% stake. Veritable L P reported 6,225 shares stake. Guardian Life Ins Of America reported 385 shares stake. 1832 Asset L P has invested 0% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Livforsakringsbolaget Skandia Omsesidigt has 0.62% invested in Quest Diagnostics Incorporated (NYSE:DGX). Dekabank Deutsche Girozentrale reported 128,743 shares. Delta Asset Mgmt Ltd Liability Co Tn has 43 shares for 0% of their portfolio. Sun Life Incorporated holds 0.01% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX) for 377 shares. Sit Invest invested 0.44% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). The Massachusetts-based Rampart Invest Mngmt Co Ltd has invested 0.03% in Quest Diagnostics Incorporated (NYSE:DGX). Sumitomo Mitsui Tru stated it has 504,926 shares. Amf Pensionsforsakring Ab reported 0.24% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Financial Architects reported 1,446 shares. Riverhead Mgmt Lc holds 0.14% in Quest Diagnostics Incorporated (NYSE:DGX) or 37,255 shares. Optimum Invest reported 0.03% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX).

Quest Diagnostics Incorporated (NYSE:DGX) Ratings Coverage

Among 8 analysts covering Quest Diagnostics (NYSE:DGX), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Quest Diagnostics has $117 highest and $90 lowest target. $101’s average target is 3.88% above currents $97.23 stock price. Quest Diagnostics had 18 analyst reports since November 30, 2018 according to SRatingsIntel. The rating was maintained by Credit Suisse with “Outperform” on Friday, November 30. The rating was maintained by Barclays Capital on Friday, November 30 with “Overweight”. Bank of America downgraded the shares of DGX in report on Thursday, January 3 to “Underperform” rating. As per Tuesday, February 19, the company rating was maintained by Credit Suisse. The stock has “Hold” rating by Argus Research on Thursday, January 31. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Neutral” rating by Goldman Sachs on Friday, November 30. The rating was maintained by Canaccord Genuity with “Buy” on Monday, February 18. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, April 24 report. Morgan Stanley maintained Quest Diagnostics Incorporated (NYSE:DGX) on Thursday, April 25 with “Overweight” rating. The rating was maintained by Morgan Stanley on Friday, November 30 with “Overweight”.

More notable recent Quest Diagnostics Incorporated (NYSE:DGX) news were published by: Finance.Yahoo.com which released: “Quest Diagnostics Incorporated’s (NYSE:DGX) Earnings Dropped -7.9%, How Did It Fare Against The Industry? – Yahoo Finance” on May 08, 2019, also Seekingalpha.com with their article: “Quest good defensive play – Baird – Seeking Alpha” published on April 23, 2019, Investorplace.com published: “4 Health Care Stocks That Are Starting to Heat Up – Investorplace.com” on April 28, 2019. More interesting news about Quest Diagnostics Incorporated (NYSE:DGX) were released by: Prnewswire.com and their article: “Quest Diagnostics Reports First Quarter 2019 Financial Results – PRNewswire” published on April 23, 2019 as well as Prnewswire.com‘s news article titled: “Forbes Names Quest Diagnostics One of America’s Best Large Employers – PRNewswire” with publication date: April 22, 2019.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.